Nursing Leadership Roles and Its Influence on the Millennial Psychiatric Nurses' Job Satisfaction and Intent to Leave.

BACKGROUND: There is an increasing need for millennial psychiatric nurses in health care. Nurses' levels of satisfaction with their manager's leadership styles are critical to their remaining in the profession. AIM: To explore the relationship between the roles of nursing leadership and their influence on the millennial psychiatric nurse's level of job satisfaction and intent to leave. METHOD: Eighty-three psychiatric registered nurses between the ages of 22 and 37 with 6 months or more experience completed a Managerial Skills and Job Satisfaction Survey questionnaire. RESULTS: The millennial psychiatric nurse who perceived their managers to display the roles in being a mentor (M = 24.95, SD = 2.81), director (M = 23.08, SD = 2.55), and monitor (M = 22.71, SD = 2.51) had higher job satisfaction and would be less likely to leave the specialty, current position, and organization. CONCLUSION: The study revealed that nursing leaders need to focus on strengthening the monitor and mentor roles and work on changing from having a coordinator role to the director role.

Obstetric Nurses' Self-Efficacy, Demographic Characteristics, and Family-Focused Care During Simulated Events.

Introduction/Background: A study involving 48 obstetric nurses explored the relationship between self-efficacy scores and demographic variables, and family-focused care during obstetrical emergencies. Methods: Obstetric Nursing Self-Efficacy Scale scores and demographic data were collected, and the Van Gelderen Family Care Rubric (VGFCR) was administered following simulation of obstetrical emergencies. Results: Two variables were found to influence the VGFCR scores. Nursing specialty certification and previous education in family-focused care. Conclusion: Improvements in the delivery of family-focused care can be achieved with simulation education and nursing specialty certification achievement.

Cross-national comparison of factors related to stressors, burnout and turnover among nurses in developed and developing countries.

AIM: To examine factors of a hypothetical model related to stressors, burnout and turnover in nurses from developed and developing countries-Canada, Japan, the United States, Malaysia and Thailand. DESIGN: A cross-sectional questionnaire-based study. METHODS: Conducted between April 2016 and October 2017, the Maslach Burnout Inventory, Intention to Leave Scale, and Nursing Stress Scale collected data from acute care hospital nurses in Canada (n = 309), Japan (n = 319), Malaysia (n = 242), Thailand (n = 211) and the United States (n = 194). RESULTS: Compared to other countries, burnout "exhaustion" was the highest in Japan and "cynicism" and intention to leave the job were the highest in Malaysia. Thailand had lower burnouts and turnover than other countries and higher professional efficacy than Japan and Malaysia. In all countries, reducing stressors is important for reducing burnout and intention to leave jobs, especially as they relate to "lack of support."

Impact of Obstetric Emergency High-Fidelity Simulation on Maternity Nurses' Self-Efficacy in the Rural Hospital Setting.

PURPOSE: The purpose of this study was to explore the impact of an obstetric emergency high-fidelity simulation on maternity nurses' perceived self-efficacy levels at three different time points. STUDY DESIGN: We used a quasi-experimental, repeated measures design. METHODS: A convenience sample of maternity nurses recruited from three institutions within a single rural health care system participated in simulation exercises at an academic high-fidelity simulation center. They completed the Obstetric Nursing Self Efficacy survey before, immediately after, and 2 months following the simulation. RESULTS: Twenty-nine nurses were included in the analysis. All were women and Caucasian. Most (72.4%) had a baccalaureate nursing degree, with an average nursing experience of 11 years (range 1 to 44 years), and <5 years of OB experience (55.1%). Self-efficacy scores were 55.62 (SD = 9.8), 58.93 (SD = 8.9), and 61.86 (SD = 9.5) for pre-, post-, and 2 months postsimulation, respectively. There were significant changes from self-efficacy scores before the simulation when compared with scores 2 months after the simulation (p < 0.001), with a medium effect size of .45. CLINICAL IMPLICATIONS: High-fidelity simulation can improve maternity nurses' perceived self-efficacy in managing emergency obstetric clinical situations. Health care institutions should consider investing in high-fidelity simulation education or partnering with academic institutions that have simulation centers to promote maternity nurses' self-efficacy that can potentially translate into improved clinical skills and improved patient outcomes.

What Influences Work Engagement Among Registered Nurses: Implications for Evidence-Based Action.

BACKGROUND: Previous studies evaluating work engagement of nurses revealed work-related factors and nurse demographics affecting work engagement. Low work engagement yields a decrease in productivity, high turnover, loss of revenue, and, most importantly, patient safety concerns. AIM: To investigate the relationship between nurse-related and work-related variables associated with work engagement and provide a model that explains work engagement. METHOD: This study employed an observational, cross-sectional study design, with 201 registered nurses working in acute care hospitals in the United States participating in the study. Four work-related and five nurse-related variables were evaluated and used in the work engagement model. A standard multiple regression was performed using the work- and nurse-related factors regressed onto work engagement. Structural equation model procedures were performed to examine the association between predictive variables and work engagement. RESULTS: Of the 201 participants, just over a third of the participants were over 50 years of age (33.5%), female (91.6%), married (68%), had a bachelor of science in nursing (58.1%), and have been a nurse <5 years (42.4%). Five of the variables were found to make a unique statistically significant contribution to the variance in work engagement, age (ß = .31, p = .001), workload (ß = .30, p < .001), Core Self-Evaluation Scale (ß = 0 .22, p = .002), Coping with Change Scale (ß = .20, p = .001), and Maslach Burnout Inventory (MBI)-General Scale score (ß = -.17, p = .03). The work engagement model indicated a satisfactory overall model fit of the model (GFI = .996; χ2 (2, N = 201) = 4.02, p = .135; RMSEA = .07; CFI = .983; NFI = .976). LINKING EVIDENCE TO ACTION: The results of this study confirm a work engagement model that incorporates both nurse- and work-related factors. Overall, the results indicate that the level of work engagement is predicted more by nurse-related factors than by work-related factors.

Perceived Fears, Barriers, and Benefits Regarding Breast Cancer Screening: A Comparison of Lebanese and Lebanese-American Women.

Breast cancer is the most prevalent malignancy among Lebanese women, and nearly half of these women are age < 50 years at diagnosis. Despite the current screening guidelines in Lebanon to start mammograms at 40 years of age, monthly self-breast examination, and yearly clinical breast examination, compliance with these recommendations remains low in both Lebanese and Lebanese-American women. This study aimed to examine different factors associated with breast cancer screening compliance in Lebanese and Lebanese-American women and determine and compare factors that predict breast cancer screening for these 2 groups. A cross-sectional study design was used to examine the factors associated with breast cancer screening compliance in Lebanese and Lebanese-American women. A total of 250 Lebanese women and 105 Lebanese-American women completed the questionnaires. Of these, 74.3% of Lebanese-American women and 72.5% of Lebanese women had ever had a mammogram, and 58.4% of Lebanese women had had a clinical breast examination, compared with 84.8% of Lebanese-American women. In both groups, health care provider recommendation was a predictor of having had a mammogram. Although the breast cancer screening practices of both groups are higher than previously reported, they continue to fall below the recommended rate of 81% according to the Healthy People Project. Given the susceptibility of Lebanese women age > 40 years to develop breast cancer, promotional breast cancer screening campaigns must emphasize the importance of adhering to screening guidelines for both Lebanese and Lebanese-American women.

Burnout, Workplace Factors, and Intent to Leave Among Hematology/Oncology Nurse Practitioners.

BACKGROUND: Burnout and intent to leave have been well documented in oncology/hematology health-care professionals, with a potentially detrimental effect on the patient-provider relationship and job satisfaction. With the recommended changes in the nurse practitioner (NP) role to accommodate for the physician shortage, it is important to determine the burnout and intent to leave of hematology/oncology NPs. PURPOSE: To examine the association between burnout, workplace factors, and intent to leave among hematology/oncology NPs. METHODS: In this cross-sectional survey, a convenience sample of 201 hematology/oncology NPs was recruited to assess their burnout levels using the Maslach Burnout Inventory, workplace factors using the Areas of Worklife survey (AWS), and intent to leave. Descriptive, correlational, and logistic regression analyses were performed to examine the relationships among variables. RESULTS: 44 (21.9%) participants reported intention to leave the profession or hematology/oncology. 30.8% of the sample reported a high level of emotional exhaustion, 9.0% reported high depersonalization, and 21.0% reported low personal accomplishment. Emotional exhaustion was related to increased likelihood of intent to leave in regression model (adjusted odds ratio [OR] = 1.10, 95% confidence interval [CI] = 1.05-1.17, p < .001). Workplace reward (adjusted OR = 0.4, 95% CI = 0.17-0.93, p < .05) and value (adjusted OR = 0.52, 95% CI = 0.28-0.99, p < .05) were negatively associated with intent to leave. CONCLUSION: Hematology/oncology NPs experience high emotional exhaustion, with over 20% indicating intent to leave their job or the nursing profession. Some workplace factors may play protective roles to reduce the intent to leave. Interventions are needed to enhance these workplace factors to decrease burnout.

Job satisfaction among oncology nurse practitioners.

BACKGROUND: One proposed solution to the predicted shortage of oncology nurse practitioners (NPs) is expanding the role of the oncology NP. However, role expansion may lead to an increase in work-related stress and a decrease in job satisfaction. It is important to understand oncology NPs' job satisfaction and stress and their intent to leave their job or profession in order to further develop and potentially expand the role. PURPOSE: The purpose of this study is to determine the main factors that affect job satisfaction, especially the relationship with stress and the intent to leave the oncology specialty. METHODS: A convenience sample of responses to a series of surveys administered by the Oncology Nursing Society and residing in the ONS database was used for this analysis. Exploratory data analysis, principal component analysis, and regression models were applied to explore characteristics of the questionnaires, assess the reliability of the Coping Skills Questionnaire, and find out main factors for their intent to leave. RESULTS: Items in the Coping Skills Questionnaire were internally consistent, and stress had a positive effect on NPs' intent to leave. Satisfaction and coping skills were also significant in some models; higher levels of satisfaction and coping skills resulted in lower levels of intent to leave. Moreover, several demographic factors such as having children, schedule days off, and patient population also affected the response significantly. IMPLICATIONS FOR PRACTICE: This study provides nursing leaders with information to guide retention of NPs.

Breast Cancer Risk Factors: a Cross- Cultural Comparison between the West and the East

Background: The incidence of breast cancer in Lebanon is higher than any other Middle ­Eastern country, is diagnosed at a younger age than women in Western countries, and is more aggressive and fatal. Therefore addressing risk factors in this population is of paramount importance. Methods: A descriptive cross-sectional, comparative design evaluated the risk factors for breast cancer in a convenient sample of 105 Lebanese-American women with 250 Lebanese. Odds Ratio, Chi square t-tests or ANOVA were used to compare the two groups' risk factors and knowledge of screening tools. Associations found to be statistically significant were included in three multiple logistic regression models to estimate the odds of each variable for performing a mammography, a clinical breast exam (CBE) and a breast self-exam (BSE). Results: There were more Muslims in the Lebanese-American sample who perceived having a better income, and had a better understanding of the effectiveness of the mammogram, the CBE and the BSE. The Lebanese group reached menopause at an older age, t = 2.66, p = 0.05, smoked more, OR = 1.42, p = 0.001 and were five times more likely to live close to a main road or highway, OR = 5.75, p = 0.001 than the Lebanese-American group. The Lebanese- Americana group breast fed longer χ2= 11.68, p = .008, used contraceptives more, OR = 1.74, p = 0.027, exercised more, OR = 1.61, p < 0.001, and consumed more vegetables and fruits than their Lebanese counterparts, OR= 1.22, p = 0.002, and OR = 1.27 p = 0.001, respectively. For ever having a mammogram, the duration of breastfeeding (>6 months), effectiveness of the mammogram, and exercise were significant predictors. While for ever having a CBE, smoking, eating fruits, and exercise were significant. No variables were related to performing a BSE. Conclusion: The Lebanese women had higher risk factors for developing breast cancer, and had less knowledge of the benefits of breast cancer screening tools, calling for the importance of promoting healthy life styles and education.

Challenges and Role Changes in Caring for Adult Children With Cancer.

CASE STUDY Here we present a case of a mother's struggle, in her own words, about defining her new role after her adult son's cancer diagnosis and the importance of practicing family-centered care in this scenario. A Mother's Role At 27 years old, my son, Stephan, received a diagnosis of testicular embryonal carcinoma with metastatic retroperitoneal adenopathy. The standard treatment recommended by the guidelines included surgery and chemotherapy. It's different when your child of young adult age is diagnosed with cancer. The dreaded words of "It's cancer" were challenging for me to hear as his mother. But those limbo years when your child is not really a child any longer add to the challenge. They are old enough to be in college or to have completed college, yet they are not fully independent and perhaps not married or with a family of their own yet. Levinson (1976) labeled this 20- to 39-year-old age range as "provisional adult," while Havighurst (1956) used the terms "young adult" or "early adulthood." As a nurse, I use these labels myself to describe these patients. However, labels cannot change the ambiguous nature of your role as you care for your young adult child who has a cancer diagnosis. Stephan had achieved many common milestones set by sociologists that serve as benchmarks in the transition to adulthood: He achieved a degree, left his childhood home, was financially independent, and was in a long-term relationship. His diagnosis seemed to make the world stop. His independence was replaced with agendas designed by various health-care providers: appointments that included ultrasounds, labs, meetings with specialists, surgery, chest port insertion, and chemotherapy treatments. My role in supporting his independence changed, too. I suddenly felt unscripted for the journey of this experience. Family Strategies A sense of ambiguity pervaded our lives. Initially, health-care providers used words such as "cancer," "aggressive," and "tumor," and they weighed heavily in our hearts. We also heard words of hope, such as "cure," and "95%." Stephan had to make decisions that were uncommon for people of his age to make about a prosthetic device, chemotherapy agents, and length of treatment. Fundamental to all this turmoil, though, was hope. Providers spoke of hope. Early on, I decided our family unit would need to focus on this to keep hope alive in my son's world. During the long and low days ahead and during times when exhaustion prevailed, we conscientiously reminded each other of hope and kept that thought illuminated in my son's world. Early on in Stephan's journey, I realized that being present in the moment helped him to be calm, rally strength, and sometimes even develop a sense of control. I encouraged our family to be considerate of being present by disengaging from technology and just being in the moment with my son, allowing his priorities to become our priorities. This went beyond sitting with him during chemotherapy infusion; it expanded into time off for his girlfriend so she could also relax and take a break. To do this, we needed to be honest with each other without judgment. If his girlfriend needed a break one evening, I could be there to give her that relief. It became apparent as the weeks of treatment turned into months that our ability to be present was facilitated by communication. My son's girlfriend and I promised one another to be open and honest in our communication. As his mother, I just wanted to be by his side, caring, cooking, and assuring his comfort. Those instinctive urges are powerful yet not realistic. My son's girlfriend and I openly discussed ways I could help: sending over a few meals, assuming responsibility for transportation to and from chemotherapy on certain days, and being the key person to keep extended family informed. I was surprised at how quickly our honest communication became a well-oiled machine of support for my son and their home life. After the last round of chemotherapy was completed, I began to reflect on how we had made it through the 4-month journey and how I was able to support my son, honoring his independence as a young adult and honoring my role as mother of a young adult with cancer. I only had one word: courage. For lack of a better explanation, I define courage as being willing and able to show up each day, face the challenges no matter how good or bad, and see the day through to the end. It takes a healthy dose of courage to be part of the support team for a loved one facing cancer treatments. The staff who cared for my son were all excellent, supportive, and informative. But they stopped short of acknowledging the uniqueness of the parent-young adult roles. I had to find my voice and design a new role that was important to me as his mother. This was vital for me and for my son. I will never stop being his mother, nor he my son.

Systemic treatment for breast cancer: chemotherapy and biotherapy agents.

OBJECTIVES: To describe current systemic chemotherapy and biotherapy breast cancer treatments to better inform clinical nursing practice. DATA SOURCES: CINAHLl, Medline, Academic Research Periodicals, PubMed Clinical Queries, CANCERLIT, and EBM Reviews-Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews (CDSR). CONCLUSION: Systemic therapeutic options for patients with breast cancer can be complex and varied. Furthermore, the guidelines for the treatment of breast cancer are frequently changing as new chemotherapies and biotherapies are being developed. IMPLICATIONS FOR NURSING PRACTICE: Nursing clinical practice has to remain current to accommodate new treatments and the side effect profiles. This knowledge is essential to providing evidence-based care for breast cancer patients receiving these treatments.

Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.

The systemic therapeutic management of breast cancer has undergone significant transformation in the past decade. Without targeted therapies, conventional treatment with cytotoxic agents has reached the limit of its potential in terms of patient survival for most types of cancer. Enhanced understanding of the pathogenesis of tumor cell growth and metastasis has led to the identification of signaling growth pathways as targets for these directed therapies. Novel therapies targeted to HER2/neu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), poly(ADP ribose) polymerase (PARP), mammalian target of rapamycin (mTOR), histone deacetylase (HDAC), the heat shock protein, and cyclin-dependent kinase (CDK) inhibitors have been developed and have demonstrated some efficacy in breast cancer. Recognition and management of the toxicities associated with targeted therapies is imperative. This review will describe the clinical development and utilization of targeted therapies currently in use or in clinical trials, with a focus on considerations for the oncology advanced practitioner.

Barriers to treatment in patients with locally advanced breast cancer.

Delays between presentation and treatment could have a significant effect on breast cancer mortality. The authors hypothesized that patient, physician, and system barriers are all responsible for treatment delays. Therefore, a study was conducted to define prevalent barriers to treatment from the patient's perspective. A modified 43-item Likert-scale questionnaire was administered to patients with clinical stage III locally advanced breast cancer (LABC) who had experienced a delay in treatment of 3 months or more. Between October 2008 and January 2010, 153 patients presented with LABC; 43 patients (28.1%) met eligibility, and 40 completed the questionnaire. Among the patient barriers reported, 38% of patients delayed care for fear of losing their breast and 47% awaited previously scheduled routine appointments instead of seeking care. Among the physician barriers reported, 20% of physicians of initial contact did not believe the breast lump/symptom was related to cancer and 15% did not believe it needed a biopsy. Among the system barriers reported, the most prevalent were delays in performing diagnostic tests and obtaining insurance authorization for tests, treatment, or physician visits. Substantial delays were seen in 28.1% of patients from presentation to when they sought therapy at City of Hope Comprehensive Cancer Center. The high prevalence of patient barriers versus physician/system barriers suggests that increased educational efforts for patients and health care professionals are needed.

Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.

Increased understanding of the molecular composition of breast cancer tumors has led to the development of targeted anticancer agents. Novel therapies directed against human epidermal growth factor receptor 2 (HER2) in breast cancer have been developed. One such agent, trastuzumab emtansine (T-DM1), is an antibody drug conjugate that has been shown to be effective in the treatment of women with HER2-positive breast cancer. Phase I and II studies have determined a maximum tolerated dose, and several phase Ib/II, II, and III studies have shown improved tolerability and efficacy compared with the combination of trastuzumab and chemotherapy. The most concerning grade 3 or higher adverse events associated with T-DM1 include thrombocytopenia and transaminitis. To ensure that these adverse events do not delay or interrupt treatment, oncology nurses need to familiarize themselves with these risks and their management. This article reviews the clinical development of T-DM1 and its usage, with a focus on the nurse's role in preventing and managing adverse events associated with T-DM1 therapy.

Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center experience.

BACKGROUND: Advances in breast cancer prevention, diagnosis, and treatment are in part the result of patient involvement in clinical trials. Despite increases in new clinical research initiatives and trials open to accrual, only 2-3% of women with breast cancer enroll. There is a need to identify the barriers interfering patient accrual. METHODS: Data were extracted from patients with breast cancer seen for treatment in 2009 retrospectively. Descriptive analysis of patient demographic on enrollment were performed using logistic regression analyses. RESULTS: Of 418 patients evaluated for treatment, 163 had a trial available; 138 of these were eligible. Eighty (58%) participated in a clinical trial; the remainder declined (24%) or were not presented for a trial by their treating physicians (76%). Age, preferred language, marital status, family history, or race/ethnicity did not predict for enrollment on a therapeutic clinical trial. Patients with stage II or III breast cancer were more likely to be enrolled on a trial compared to patients with stage 0 or I (odds ratio 2.89, 9.17; p=.02, .0005 respectively). CONCLUSIONS: Enrollment of breast cancer patients on therapeutic clinical trials was relatively high (58% eligible, 19% overall). Prospective studies observing breast cancer stage, clinical trial design, and inclusion of community based physician practices would add breadth to the understanding of poor accrual to breast cancer clinical trials.

Metaplastic Breast Carcinoma in the Lungs: A Case Report.

Metaplastic carcinoma of the breast is a rare, aggressive form of cancer occurring in less than 1% of all breast cancers. Spindle cell carcinoma is a rare variant of the metaplastic carcinoma seen in less than 10% of such cases. The prognosis of spindle cell breast cancers is poor, hence aggressive treatment with surgery, chemotherapy and/or radiation is required. Here we report a case of a 62-year-old female with metastatic metaplastic breast cancer to the lungs.

Assessment of chemotherapy-induced nausea and vomiting in women with breast cancer: a Neuman systems model framework.

The importance of nursing theory and models for the development of the nursing profession is becoming increasingly evident in literature. This article demonstrates the use of the Betty Neuman Systems Model (NSM) to assess, as well as determine the predictors of chemotherapy-induced nausea and vomiting (CINV) in patients diagnosed with breast cancer receiving doxorubicin-based chemotherapy. The selection of the model for practice reflects the congruency between the level of severity of CINV and the patient-related risk factors. In addition, the NSM was used to determine the appropriate nursing interventions necessary to strengthen the flexible lines of defense and the lines of resistance in addition to maintaining system stability.

Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy.

BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) remain among the most frequently reported distressing side effects associated with anthracycline-based chemotherapy despite significant advances in antiemetic management. The main risk factor for severity of CINV is the emetogenic potential of the chemotherapeutic agents. However, patient-related risk factors have been identified, including genetic makeup. Although studies have noted that ethnicity influences nausea and vomiting in other contexts, there is a paucity of research regarding the impact of ethnicity on CINV. This study was undertaken to evaluate whether Asian women receiving anthracycline-based chemotherapy experience more CINV than non-Asians. METHODS: A retrospective, comparative, correlational chart review was performed to abstract the relevant variables. RESULTS: Data from a convenience sample of 358 women with breast cancer who received chemotherapy with doxorubicin between 2004 and 2008 at City of Hope in Duarte, California, were evaluated. The sample consisted of Caucasians (45%), Hispanics (27.7%), Asians (19.8%), and African Americans (7.5%). The results indicate that Asian women with breast cancer undergoing anthracycline-based chemotherapy experienced statistically significantly more clinically important CINV than their non-Asian counterparts. LIMITATIONS: The data were collected retrospectively, with a certain population distribution at a specific time. CONCLUSION: This study provides interesting preliminary evidence that Asian ethnicity plays a role in the development of severe CINV. When managing chemotherapy toxicities in women with breast cancer, health-care providers should tailor therapy to individual risk profiles. Specifically, consideration of antiemetic therapy should accommodate patient characteristics, such as Asian descent.

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

The rapid evolution of targeted therapies has had a dramatic impact on multiple domains in oncology, particularly metastatic renal cell carcinoma (RCC). Four agents antagonizing vascular endothelial growth factor-mediated signaling have been approved for the treatment of metastatic RCC, including the monoclonal antibody bevacizumab and the small molecular inhibitors sunitinib, sorafenib, and pazopanib. Pazopanib was approved in 2009 for this disease on the basis of a phase III clinical trial demonstrating a superior progression-free survival compared to placebo in 435 patients with either treatment-naive or cytokine-refractory disease. The trial offered insight related to the toxicity profile associated with this agent. The most common clinical adverse events are diarrhea, hypertension, nausea, anorexia, and vomiting. With respect to laboratory adverse events, hepatotoxicity represents a specific concern with pazopanib. Oncology nurses play a critical role in counseling patients regarding the toxicity profile and management of adverse events in pazopanib treatment.

Diffuse large B-cell lymphoma with calf muscle localization.

Although diffuse large B-cell lymphoma (DLBCL) usually occurs in the lymph nodes, approximately 30-40% of the time it can have an extranodal site of involvement and it can arise in nearly every body site such as intestine, bone, breast, liver, skin, lung, and central nervous system. Muscle involvement of DLBCL is especially uncommon, comprising 0.5% of extranodal NHL. We report a case of a 72-year-old man with extranodal DLBCL of a unique manifestation in the calf muscle, involving predominantly the gastrocnemius muscle. The patient achieved complete response and remained free of local recurrence or metastasis following diagnosis.